Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

[1]  M. Kozioł,et al.  Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group , 2021, Journal of clinical apheresis.

[2]  P. Hari,et al.  Salvage second transplantation in relapsed multiple myeloma , 2020, Leukemia.

[3]  G. Gahrton,et al.  Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? A review from the Chronic Malignancies Working Party of the EBMT. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  M. Liedtke,et al.  Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. , 2019, Best practice & research. Clinical haematology.

[5]  P. L. Bergsagel,et al.  Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement , 2018, Bone Marrow Transplantation.

[6]  H. Goldschmidt,et al.  Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  W. Wiktor-Jedrzejczak,et al.  Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. , 2018, Biology of Blood and Marrow Transplantation.

[8]  W. Wiktor-Jedrzejczak,et al.  Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party , 2017, Haematologica.

[9]  H. Goldschmidt,et al.  Cyclophosphamide‐based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE , 2017, European journal of haematology.

[10]  J. Snowden,et al.  Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  B. Barlogie,et al.  Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia , 2014, Leukemia.

[12]  A. Krishnan,et al.  SECOND TRANSPLANTS FOR MULTIPLE MYELOMA RELAPSING AFTER A PRIOR AUTOTRANSPLANT – REDUCED INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS TRANSPLANTATION , 2013, Bone Marrow Transplantation.

[13]  J. Vose,et al.  Salvage second hematopoietic cell transplantation in myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Yunfeng Dai,et al.  Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation , 2013, Journal of clinical medicine research.

[15]  D. Dingli,et al.  Second auto-SCT for treatment of relapsed multiple myeloma , 2013, Bone Marrow Transplantation.

[16]  H. Eom,et al.  Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT , 2013, Bone Marrow Transplantation.

[17]  P. Moreau,et al.  Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  D. Marin,et al.  Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation , 2013, Leukemia & lymphoma.

[19]  M. Solh,et al.  Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT , 2013, Bone Marrow Transplantation.

[20]  P. Thall,et al.  Durable remission with salvage second autotransplants in patients with multiple myeloma , 2012, Cancer.

[21]  S. Trudel,et al.  Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  G. Morgan,et al.  Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  I. Bruns,et al.  Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation , 2011, Leukemia & lymphoma.

[24]  J. Snowden,et al.  Re‐transplantation after bortezomib‐based therapy , 2011, British journal of haematology.

[25]  W. Wiktor-Jedrzejczak,et al.  Haematopoietic stem cell mobilization with plerixafor and G‐CSF in patients with multiple myeloma transplanted with autologous stem cells , 2011, European journal of haematology.

[26]  D. Porter,et al.  Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma , 2009, Bone Marrow Transplantation.

[27]  C. Frei,et al.  Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma , 2009, Leukemia & lymphoma.

[28]  A. Piccin,et al.  Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma , 2006, American journal of hematology.

[29]  M. Qazilbash,et al.  Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma , 2006, Cancer.

[30]  B. Barlogie,et al.  Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? , 1998, Bone Marrow Transplantation.

[31]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[32]  Larocca,et al.  Second primary malignancies in multiple myeloma: an overview and IMWG consensus. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.